Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivarmacitinib for Moderate-to-Severe Oral Lichen Planus
ChiCTR2600127194Phase 4Not yet recruiting
- Sponsor
- Xijing Hospital
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in oral lichen planus (OLP) comparing Ivarmacitinib + triamcinolone acetonide with Placebo then ivarmacitinib + triamcinolone acetonide (2 arms). Primary endpoint: Oral Disease Severity Score at week 20. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
ivarmacitinib
03
Conditions
oral lichen planus (OLP)
Beyond the preview
Go deeper on ChiCTR2600127194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600127194.